On Monday June 22, Gilead Sciences introduced it’s making ready to kick off a trial testing an inhalable model of the investigational COVID-19 drug remdesivir. Via an open letter penned by chairman and CEO Daniel O’Day, the corporate reported it’s about to screening wholesome volunteers this week, within the hopes of beginning a trial in August.
Remdesivir is an antiviral drug that has been accepted to deal with COVID-19 sufferers. To date, the remedy has been administered intravenously; the corporate hopes delivering the drug by way of a nebulizer might permit for simpler dosing exterior hospitals to sufferers within the earlier levels, serving to to stem the progress of the illness.
In the letter, O’Day pointed at earlier research exhibiting remdesivir’s potential in treating COVID-19 sufferers. A National Institute of Allergy and Infectious Diseases (NIAID) randomized, managed trial reportedly confirmed the drug shortened restoration time by a median of 4 days, and Gilead’s SIMPLE study of reasonable sufferers confirmed higher medical outcomes with a five-day remdesivir course than these receiving normal of care.
O’day additionally identified the NIAID study indicated remedy labored finest in sufferers who didn’t but want air flow, indicating additional study in sufferers within the early levels of the illness was warranted.
“The totality of these data shows that remdesivir has the potential to be of meaningful benefit to patients with COVID-19 and offers important hope,” O’Day wrote. “In our ongoing studies, we will work to deliver on that hope and potentially benefit more patients.”